Advancing Regenerative Medicine
SMSbiotech is a clinical-stage regenerative medicine company developing a first-in-class Small Mobile Stem (SMS) cell therapy platform. Its lead COPD program has demonstrated early safety and encouraging efficacy signals in Phase 1b and is advancing toward U.S. clinical development and Phase 2.
Small Mobile Stem (SMS) cells, derived from adult human blood, are designed as an allogeneic, off-the-shelf therapy with the ability to engage key regenerative pathways. The platform is built to overcome limitations of existing cell therapies while enabling scalable, repeatable treatment approaches.
Democratizing the application of adult stem cell technologies for human health.
Regenerative Medicine Enabled by a Novel superior Stem Cell Technology
join usCurrently, many conventional drugs and treatments address patients’ symptoms instead of the root causes of the disease. This approach can result in ongoing health issues like non-healing wounds, degenerative tissues or diseases we merely live with like Chronic Obstructive Pulmonary Disease (COPD), a third leading cause of death worldwide. About 3.5 million death every year according to the WHO.
SMSbiotech’s patented regenerative technology intends to change this status quo. Its approach addresses the lack of ability of many patients to restore cells and tissues damaged by disease, trauma, and aging to positively affect their quality of life and longevity.
A novel, patented approach that produces unique human allogeneic adult Small Mobile Stem (SMS) cells.
The backbone of our treatments
Stem cell enabling technology. Delivering life-changing treatments from human stem cells with unique properties and derived complex proteins.
more infoA novel, patented approach that produces unique human allogeneic adult Small Mobile Stem (SMS) cells.
The challenges
Tissue degeneration is at the root of many chronic and age-related diseases such as COPD, ARDS, and chronic wounds.
more info
Our technological
solutions
Cutting edge technology addressing the two essential components of living tissue; cells and extracellular matrix.
more infoManufactures cells for therapeutic use at an industrial scale. These cells can successfully address chronic lung diseases such as COPD.
Who we are
SMSbiotech is a clinical-stage regenerative medicine company founded in 2015 and based in California. The Company is advancing a proprietary Small Mobile Stem (SMS) cell therapy platform designed to enable systemic, off-the-shelf regenerative treatments.
The platform is based on the discovery of a novel population of adult stem cells derived from human blood and protected by a growing global patent portfolio. These cells are designed to support scalable manufacturing, stability, and repeatable dosing, addressing key limitations of traditional cell therapies.
SMSbiotech has established clinical-stage biomanufacturing capabilities, including ISO-7 clean room infrastructure, enabling controlled, reproducible production aligned with regulatory requirements. SMS cells are capable of ex vivo expansion without loss of potency, supporting the potential for industrial-scale manufacturing.
The Company is currently advancing its lead COPD program through Phase 1b clinical development, with early safety and encouraging efficacy signals observed. SMSbiotech is focused on progressing toward U.S. regulatory pathways and expanding into Phase 2 clinical studies.
The team combines expertise across regenerative biology, clinical development, and capital markets, working to translate scientific discovery into clinically meaningful therapies for patients with chronic and degenerative diseases
Do you want to learn more about us? Contact us!
